Module 1 (US) — Form 356h & Cover Letter (OBX-319)
📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Module 1 (US) — Form 356h & Cover Letter (OBX-319)
Why it exists. Region-specific administrative content the agency requires in front of the scientific dossier.
How it is produced here. This is a region-specific administrative document, assembled to the local filing and labeling conventions. Its operational and label content is written to stay consistent with the (simulated) clinical data.
Format & governing standard. —
Module 1 (US) — Form 356h & Cover Letter (OBX-319)
Document ID: M1-356h
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): 21 CFR 314/601
FDA Form 356h & Cover Letter — OBX-319
Application to market a new drug/biologic for OBX-319 (sponsor Virtual Biopharma Inc.). The cover letter identifies the application type, the proposed indication (Systemic Lupus Erythematosus (moderate-to-severe active)), and the pivotal study OBX319-301; the 356h captures the administrative and establishment particulars. Application number to be assigned. 21 CFR 314/601; eCTD US regional.
Comments (0)
No comments yet. Be the first to say something!